keliximab

intra-articular primatised anti-CD4 antibody for treatment of rheumatoid knee

Also Known As:

CE 9.1; CE9.1; SB 210396; SB-210396

Networked: 8 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        keliximab: 8
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        keliximab: 8
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        keliximab: 8

Experts

1.	Bugelski, P J: 3 articles (09/2002 - 04/2000)
2.	Hart, T K: 3 articles (09/2002 - 04/2000)
3.	Herzyk, D J: 3 articles (09/2002 - 04/2000)
4.	Wier, P J: 2 articles (09/2002 - 04/2000)
5.	Harmsen, A G: 2 articles (02/2001 - 04/2000)
6.	Truneh, A: 2 articles (04/2000 - 02/2000)
7.	Davis, C B: 1 article (01/2003)
8.	Hepburn, T W: 1 article (01/2003)
9.	Totoritis, M C: 1 article (01/2003)
10.	Aldrich, Jose: 1 article (02/2002)

Related Diseases

1.	Autoimmune Diseases (Autoimmune Disease) 02/01/2001 - "Therefore, keliximab therapy may be beneficial in controlling certain autoimmune diseases."
2.	Neoplasms (Cancer) 04/01/2000 - "In addition, immunotoxicity studies were conducted in these mice with Candida albicans, Pneumocystis carinii and B16 melanoma cells to assess the effects of keliximab on host resistance to infection and immunosurveillance to neoplasia. " 02/01/2001 - "Resistance to experimental B16 melanoma metastases was not affected by treatment with keliximab, in contrast to an increase in tumor colonization caused by anti-T cell Thy1.2 and anti-asialo GM-1 antibodies. "
3.	Experimental Melanoma 04/01/2000 - "In addition, immunotoxicity studies were conducted in these mice with Candida albicans, Pneumocystis carinii and B16 melanoma cells to assess the effects of keliximab on host resistance to infection and immunosurveillance to neoplasia. " 02/01/2001 - "Resistance to experimental B16 melanoma metastases was not affected by treatment with keliximab, in contrast to an increase in tumor colonization caused by anti-T cell Thy1.2 and anti-asialo GM-1 antibodies. "
4.	Infections 09/01/2002 - "The potential effects of exposure to treating maternal mice (F0) with keliximab during pregnancy and lactation on offspring viability, physical growth, neurobehavioral development, reproductive function, lymphoid tissue morphological structure, lymphocyte subsets and host resistance to Candida albicans infection were assessed. " 04/01/2000 - "In addition, immunotoxicity studies were conducted in these mice with Candida albicans, Pneumocystis carinii and B16 melanoma cells to assess the effects of keliximab on host resistance to infection and immunosurveillance to neoplasia. "
5.	Asthma (Bronchial Asthma) 10/03/1998 - "Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma." 07/01/2001 - "The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma." 10/03/1998 - "We investigated the efficacy and safety in severe corticosteroid-dependent asthma of a single intravenous infusion of keliximab (IDEC CE9.1), a chimeric monoclonal antibody to CD4. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	keliximab
3.	Interleukin-4 (Interleukin 4)
4.	Antibodies
5.	Adrenal Cortex Hormones (Corticosteroids)
6.	clenoliximab
7.	Thomsen-Friedenreich antibodies

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Infusions